New combo therapy aims to prevent chronic lung disease in tiniest preemies

NCT ID NCT06855043

First seen Nov 15, 2025 · Last updated Jun 15, 2026 · Updated 35 times

Summary

This study tests whether giving a lung medication (surfactant) mixed with an anti-inflammatory drug (budesonide) to extremely premature babies (born before 29 weeks) who are still on a breathing machine at 7-14 days old can safely prevent a serious lung condition called bronchopulmonary dysplasia. About 24 infants will be enrolled to check for immediate side effects and breathing improvements. The goal is to find a better way to protect these fragile babies' lungs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE MECHANICAL VENTILATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • American Family Children's Hospital

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Meriter Hospital

    Madison, Wisconsin, 53715, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.